We are live on
!
Find out more
BBA
Baker Bros. Advisors Portfolio holdings
AUM
$20B
1-Year Est. Return
154.41%
This Fund
S&P 500
This Quarter
Est. Return
+22.23%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$20B
AUM Growth
+$2.54B
(+15%)
Cap. Flow
+$128M
Cap. Flow
% of AUM
0.64%
Top 10 Holdings %
Top 10 Hldgs %
72.82%
Holding
92
New
8
Increased
16
Reduced
7
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Revolution Medicines
RVMD
|
+$276M |
| 2 |
Insmed
INSM
|
+$166M |
| 3 |
IDEAYA Biosciences
IDYA
|
+$32.6M |
| 4 |
FTH
Faeth Therapeutics
FTH
|
+$29.8M |
| 5 |
Relay Therapeutics
RLAY
|
+$24.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Edgewise Therapeutics
EWTX
|
+$99.1M |
| 2 |
ABVX
Abivax
ABVX
|
+$97.5M |
| 3 |
Summit Therapeutics
SMMT
|
+$63.9M |
| 4 |
Spyre Therapeutics
SYRE
|
+$50.4M |
| 5 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$26.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.65% |
| 2 | Miscellaneous | 0.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Protara Therapeutics
TARA
$226M
| $3.71M | 0.02% |
971,614
| – | – |
|
77
TScan Therapeutics
TCRX
$51.1M
| $2.73M | 0.01% |
2,784,792
| – | – |
|
78
Immunome
IMNM
$3.13B
| $1.17M | 0.01% |
+55,306
| New | +$1.18M |
|
79
Skye Bioscience
SKYE
$7.84M
| $1.09M | 0.01% |
196,905
| – | – |
|
80
Sana Biotechnology
SANA
$1.18B
| $1.08M | 0.01% |
310,483
| – | – |
|
81
Aligos Therapeutics
ALGS
$43.1M
| $479K | ﹤0.01% |
83,055
| – | – |
|
82
Tyra Biosciences
TYRA
$1.49B
| $339K | ﹤0.01% |
10,607
| – | – |
|
|
SRZNW
83
DELISTED
Surrozen Inc Warrant
SRZNW
| $13.8K | ﹤0.01% |
833,333
| – | – |
|
|
ABVX
84
Abivax
ABVX
$9.89B
| – | – |
-875,796
| Closed | -$97.5M |
|
85
argenx
ARGX
$64B
| – | – |
-25,174
| Closed | -$18.4M |
|
|
CMPS
86
Compass Pathways
CMPS
$1.9B
| – | – |
-2,344,720
| Closed | -$13M |
|
|
CNTA
87
DELISTED
Centessa Pharmaceuticals
CNTA
| – | – |
-670,751
| Closed | -$26.6M |
|
88
Immunocore
IMCR
$1.89B
| – | – |
-734,397
| Closed | -$22.1M |
|
89
Pharvaris
PHVS
$2.48B
| – | – |
-375,000
| Closed | -$10.6M |
|
|
90
Spyre Therapeutics
SYRE
$7.97B
| – | – |
-1,000,000
| Closed | -$50.4M |
|
|
CTNM
91
Contineum Therapeutics
CTNM
$641M
| – | – |
-1,420,838
| Closed | -$18.6M |
|
Similar funds
ASRS
FWIA
CWP
SFA
MGP
JAM
Baker Bros. Advisors's Q2 2026 Portfolio in Review
As of Q2 2026, Baker Bros. Advisors held 92 positions worth $20B, up 15% from $17.4B the previous quarter. Its ten largest holdings account for 73% of the portfolio.
Baker Bros. Advisors's Q2 2026 filing shows 8 new, 16 increased, 7 reduced and 9 closed positions. Its largest new stake was Faeth Therapeutics: 1,286,411 shares worth $32.2M. The largest sale was Edgewise Therapeutics, an estimated $99.1M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.
- Baker Bros. Advisors's largest Q2 2026 buy was Faeth Therapeutics: 1,286,411 shares worth $32.2M.
- Baker Bros. Advisors added most to Revolution Medicines in Q2 2026, an estimated $276M increase.
- Baker Bros. Advisors's biggest Q2 2026 reduction was Edgewise Therapeutics, cutting an estimated $99.1M.
- Baker Bros. Advisors fully exited Abivax in Q2 2026, selling an estimated $97.5M.
- Baker Bros. Advisors's ten largest holdings make up 73% of its $20B portfolio in Q2 2026.
- Baker Bros. Advisors opened 8 new positions and closed 9 in Q2 2026.
- Baker Bros. Advisors's portfolio value rose 15% quarter-over-quarter to $20B.
Based on Baker Bros. Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.